Next Article in Journal
Vertical Transmission of SARS-CoV-2 Infection and Miscarriage in the Second Trimester: Report of an Immunohistochemically Proven Case
Previous Article in Journal
Association between Empagliflozin Use and Electrocardiographic Changes
 
 
Review

A Scoping Review on the Reported Evidence and Gaps of the Risk of Diabetes in Dyslipidemic Patients under Statin Therapy

1
Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Chennai 600-123, Tamil Nadu, India
2
CUNY Graduate School of Public Health & Health Policy, New York, NY 10027, USA
3
SMAART Population Health Informatics Intervention Center, Foundation of Healthcare Technologies Society, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Chennai 600-123, Tamil Nadu, India
4
Departments of Biochemistry, Medical Education, Molecular Virology, Research, Clinical Skills & Simulation, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Chennai 600-123, Tamil Nadu, India
*
Author to whom correspondence should be addressed.
Academic Editor: Fernando Cordido
Clin. Pract. 2022, 12(4), 565-578; https://doi.org/10.3390/clinpract12040060
Received: 20 May 2022 / Revised: 7 July 2022 / Accepted: 8 July 2022 / Published: 18 July 2022
With the increasing global burden of dyslipidemia over the past 30 years, it is estimated that more than 200 million people worldwide are under statin therapy. In India, roughly 25–30% of urban populations and 15–20% of rural populations have abnormal lipid levels. Statin, which is deemed to be the gold standard lipid-lowering agent, is the first treatment of choice for these patients. Although statins at one end are highly effective against dyslipidemiaand cardiovascular diseases, at the other end, they cause adverse effects including an increased risk of diabetes mellitus. The objective of this study was to understand the coexistence of diabetes and dyslipidemia in patients undergoing statin therapy. A scoping review was conducted with published articles selected from PubMed and Google Scholar. The obtained results were filtered based on inclusion/exclusion criteria. Our database search provided a total of 822 articles, of which 48 were selected for this review, with results concluding that statin users are potentially at a greater risk of developing diabetes mellitus compared with patients who are not using statins. Although many studies have been conducted to ascertain the onset of diabetes mellitus amongst statin users, the exact mechanism is not yet precisely established. Future studies are essential for identifying the exact cause of diabetes mellitus in statin users. View Full-Text
Keywords: statins; diabetes mellitus; dyslipidemia; insulin resistance; new-onset diabetes mellitus statins; diabetes mellitus; dyslipidemia; insulin resistance; new-onset diabetes mellitus
Show Figures

Figure 1

MDPI and ACS Style

Needamangalam Balaji, J.; Prakash, S.; Joshi, A.; Surapaneni, K.M. A Scoping Review on the Reported Evidence and Gaps of the Risk of Diabetes in Dyslipidemic Patients under Statin Therapy. Clin. Pract. 2022, 12, 565-578. https://doi.org/10.3390/clinpract12040060

AMA Style

Needamangalam Balaji J, Prakash S, Joshi A, Surapaneni KM. A Scoping Review on the Reported Evidence and Gaps of the Risk of Diabetes in Dyslipidemic Patients under Statin Therapy. Clinics and Practice. 2022; 12(4):565-578. https://doi.org/10.3390/clinpract12040060

Chicago/Turabian Style

Needamangalam Balaji, Jyotsna, Sreenidhi Prakash, Ashish Joshi, and Krishna Mohan Surapaneni. 2022. "A Scoping Review on the Reported Evidence and Gaps of the Risk of Diabetes in Dyslipidemic Patients under Statin Therapy" Clinics and Practice 12, no. 4: 565-578. https://doi.org/10.3390/clinpract12040060

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop